Skip to main content

Novo Nordisk A S

NVO
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0000353278

No open-market purchases or sales by Novo Nordisk A S insiders were filed in the last 90 days; 1,355 institutions reported holding it in 13F filings for Q2 2026, worth $15.7B in total; superinvestors Markel Group and Maverick Capital hold it.

Other share classesNONOF

13F holders, Q1 2021

Institutional positions in Novo Nordisk A S as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
708
No complete 13F data for Q4 2020
Shares held
131.9M
No complete 13F data for Q4 2020
Total value
$8.87B
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting NVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 708 institutions
Q1 2021: 708 institutionsQ2 2021: 737 institutionsQ3 2021: 806 institutionsQ4 2021: 887 institutionsQ1 2022: 902 institutionsQ2 2022: 934 institutionsQ3 2022: 908 institutionsQ4 2022: 1,050 institutionsQ1 2023: 1,148 institutionsQ2 2023: 1,198 institutionsQ3 2023: 1,308 institutionsQ4 2023: 1,512 institutionsQ1 2024: 1,746 institutionsQ2 2024: 1,867 institutionsQ3 2024: 1,787 institutionsQ4 2024: 1,670 institutionsQ1 2025: 1,535 institutionsQ2 2025: 1,486 institutionsQ3 2025: 1,401 institutionsQ4 2025: 1,421 institutionsQ1 2026: 1,278 institutionsQ2 2026: 1,355 institutions
Value heldQ1 2021: $8.87B
Q1 2021: $8.87BQ2 2021: $11.0BQ3 2021: $12.7BQ4 2021: $14.7BQ1 2022: $15.2BQ2 2022: $16.4BQ3 2022: $13.8BQ4 2022: $19.4BQ1 2023: $22.1BQ2 2023: $23.2BQ3 2023: $27.4BQ4 2023: $32.2BQ1 2024: $41.8BQ2 2024: $47.9BQ3 2024: $39.7BQ4 2024: $29.1BQ1 2025: $22.5BQ2 2025: $21.3BQ3 2025: $16.7BQ4 2025: $16.0BQ1 2026: $12.0BQ2 2026: $15.7B
Institutions holding NVO and their total value by quarter
QuarterHoldersValue
Q2 20261,355$15.7B
Q1 20261,278$12.0B
Q4 20251,421$16.0B
Q3 20251,401$16.7B
Q2 20251,486$21.3B
Q1 20251,535$22.5B
Q4 20241,670$29.1B
Q3 20241,787$39.7B
Q2 20241,867$47.9B
Q1 20241,746$41.8B
Q4 20231,512$32.2B
Q3 20231,308$27.4B
Q2 20231,198$23.2B
Q1 20231,148$22.1B
Q4 20221,050$19.4B
Q3 2022908$13.8B
Q2 2022934$16.4B
Q1 2022902$15.2B
Q4 2021887$14.7B
Q3 2021806$12.7B
Q2 2021737$11.0B
Q1 2021708$8.87B

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding Novo Nordisk A S.

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding NVO in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
State Street Corp4,017,159$274.5M0.02%––
Folketrygdfondet4,249,410$286.5M9.78%––
Fayez Sarofim & Co4,965,355$334.8M1.23%––
Capital International Investors5,072,371$343.4M0.09%––
Loomis Sayles & Co L P6,675,375$450.1M0.58%––
Bank of America Corp7,495,333$505.3M0.06%––
Fisher Asset Management, LLC16,054,695$1.08B0.76%––
Renaissance Technologies LLC24,846,671$1.68B2.08%––